Published in Oncoimmunology on October 21, 2013
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol (2016) 0.91
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology (2014) 0.82
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunol Res (2016) 0.82
Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. Biomed Res Int (2015) 0.81
Role of HLA-G and extracellular vesicles in renal cancer stem cell-induced inhibition of dendritic cell differentiation. BMC Cancer (2015) 0.81
The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget (2016) 0.81
HLA-G expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med (2015) 0.79
Significance of tumour cell HLA-G5/-G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients. J Cell Mol Med (2015) 0.78
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. Oncoimmunology (2015) 0.76
Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer. Cancer Sci (2015) 0.75
Association of HLA-A and Non-Classical HLA Class I Alleles. PLoS One (2016) 0.75
HLA-E(⁎)01:03 Allele in Lung Transplant Recipients Correlates with Higher Chronic Lung Allograft Dysfunction Occurrence. J Immunol Res (2016) 0.75
The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. J Immunol Res (2016) 0.75
Cancer treatment and the KIR-HLA system: an overview. Clin Exp Med (2017) 0.75
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol (2017) 0.75
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Regulation of cutaneous malignancy by gammadelta T cells. Science (2001) 5.83
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci U S A (1987) 2.77
The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol (1997) 2.36
HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. J Immunol (1988) 1.73
TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol (1998) 1.70
A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med (2002) 1.67
Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood (2006) 1.65
HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 1.63
Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol (2003) 1.60
Tolerization of dendritic cells by HLA-G. Eur J Immunol (2005) 1.57
Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood (2008) 1.56
Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem (2006) 1.52
Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol (1990) 1.48
IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol (1999) 1.46
HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J (2005) 1.42
Trogocytosis-based generation of suppressive NK cells. EMBO J (2007) 1.40
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol (2003) 1.36
HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res (2005) 1.35
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol (2001) 1.35
Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element. J Exp Med (1990) 1.33
HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol (2003) 1.33
Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway. Proc Natl Acad Sci U S A (2008) 1.32
Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A (2001) 1.32
Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol (2000) 1.24
Analysis of HLA-E expression in human tumors. Immunogenetics (2003) 1.23
Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood (2007) 1.20
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol (2006) 1.20
HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest (2010) 1.18
Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens (2003) 1.18
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17
Nonclassical HLA-G molecules are classical peptide presenters. Curr Biol (1996) 1.16
Selective export of HLA-F by its cytoplasmic tail. J Immunol (2006) 1.15
Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood (2006) 1.13
HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res (2003) 1.13
Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E. J Immunol (2001) 1.11
HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol (2005) 1.09
The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci (2012) 1.08
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer (2001) 1.06
High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med (2011) 1.04
Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol (1999) 1.03
A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. Mol Biol Evol (2011) 1.03
HLA-F is a surface marker on activated lymphocytes. Eur J Immunol (2010) 1.03
Soluble HLA-G in rheumatoid arthritis. Hum Immunol (2006) 1.02
Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. Eur J Immunol (2005) 1.02
Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol (2008) 1.01
Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol (2003) 1.01
Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood (2011) 1.00
HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer (2012) 1.00
The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur J Immunol (2004) 1.00
Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol (2000) 0.99
HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol (2003) 0.97
Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. Transpl Immunol (2006) 0.96
Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur J Immunol (1999) 0.96
Requirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-E. J Biol Chem (2003) 0.93
Antigen-presenting function(s) of the non-classical HLA-E, -F and -G class I molecules: the beginning of a story. Res Immunol (1996) 0.93
HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol (2000) 0.93
HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol (2012) 0.92
Soluble HLA-G and control of angiogenesis. J Reprod Immunol (2007) 0.91
Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum Immunol (2003) 0.91
Definitive high resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele data. Tissue Antigens (2002) 0.90
Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp (Warsz) (2011) 0.89
Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transpl Immunol (2007) 0.89
Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. Mol Cell Biochem (2013) 0.88
Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding. J Exp Med (1992) 0.88
Modulation of HLA-G expression in human neural cells after neurotropic viral infections. J Virol (2005) 0.87
Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One (2011) 0.86
Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol (2003) 0.85
HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med (2012) 0.85
HLA-G expression is a fundamental prerequisite to pregnancy. Hum Immunol (2006) 0.85
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer (2002) 0.84
HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer (2011) 0.83
Detection of anti-HLA-F antibodies in sera from cancer patients. Anticancer Res (2004) 0.83
Lentiviral vectors: a versatile tool to fight cancer. Curr Mol Med (2013) 0.82
Expression of soluble HLA-G identifies favorable outcomes in liver transplant recipients. Transplantation (2010) 0.82
Full-length HLA-G1 and truncated HLA-G3 differentially increase HLA-E surface localization. Hum Immunol (2012) 0.82
Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. Hum Immunol (2000) 0.81
Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma. Int J Cancer (2012) 0.81
Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection. J Infect Dis (2009) 0.81
Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology. Autoimmun Rev (2005) 0.80
Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. Pathol Res Pract (2011) 0.79
Analysis of HLA class Ib gene expression in male gametogenic cells. Eur J Immunol (1997) 0.78
HLA class I/NK cell receptor interaction in early human decidua basalis: possible functional consequences. Chem Immunol Allergy (2005) 0.76